GLP-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
In the phosphatidylinositol signal pathway, the extracellular signal molecule binds with the G-protein receptor (Gq) on the cell surface and activates phospholipase C, which is located on the plasma membrane. The lipase hydrolyzes PIP2 into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds with the IP3 receptor in the membrane of the smooth endoplasmic reticulum and mitochondria to open Ca2+ channels. DAG helps activate protein kinase C (PKC), which phosphorylates many other proteins, changing their catalytic activities, leading to cellular responses. The effects of Ca2+ are also remarkable: it cooperates with DAG in activating PKC and can activate the CaM kinase pathway, in which calcium-modulated protein calmodulin (CaM) binds Ca2+, undergoes a change in conformation, and activates CaM kinase II, which has unique ability to increase its binding affinity to CaM by autophosphorylation, making CaM unavailable for the activation of other enzymes. The kinase then phosphorylates target enzymes, regulating their activities. The two signal pathways are connected together by Ca2+-CaM, which is also a regulatory subunit of adenylyl cyclase and phosphodiesterase in the cAMP signal pathway.
Leucine-rich repeat protein SHOC-2 is a protein that in humans is encoded by the SHOC2 gene. This protein was initially identified in Caenorhabditis elegans as SUR-8/SOC2 and was found to be a critical positive regulator of the ERK1/2 signaling pathway that integrates the Ras and RAF components of the ERK1/2 pathway into a multiprotein complex. Specifically, SHOC2 tethers RAS and PP1C proteins and in close proximity to RAF to dephosphorylate “S259” to enable MAPK signaling. The best-studied role of SHOC2 is in modulating signals of the extracellular signal-regulated kinase 1 and 2 (ERK1/2) pathway by forming a holophosphatase complex that activates RAF proteins.
Active hexose correlated compound (AHCC) is an alpha-glucan rich nutritional supplement produced from shiitake (Lentinula edodes). The product is a subject of research as a potential anti-cancer agent. AHCC is a popular alternative medicine in Japan. AHCC is a registered trademark of and manufactured by Amino Up Co., Ltd. in Sapporo City, Hokkaido, Japan. AHCC was developed by Amino Up Co., LTD. and Toshihiko Okamoto (School of Pharmaceutical Sciences, University of Tokyo) in 1989. Polysaccharides form a large part of the composition of AHCC. These include beta-glucan (β-glucan) and partially acylated α-glucan. Partially acylated α-glucan, produced by the patented long term culturing process, is unique to AHCC. Approximately 20% of the make up of AHCC is α-glucans. Glucans are saccharides, of which some are known to have immune stimulating effects.
PHLPP is a member of the PPM family of phosphatases, which requires magnesium or manganese for their activity and are insensitive to most common phosphatase inhibitors, including [okadaic acid]. PHLPP1 and PHLPP2 have a similar domain structure, which includes a putative Ras association domain, a pleckstrin homology domain, a series of leucine-rich repeats, a PP2C phosphatase domain, and a C-terminal PDZ ligand. PHLPP1 has two splice variants, PHLPP1α and PHLPP1β, of which PHLPP1β is larger by approximately 1.5 kilobase pairs. PHLPP1α, which was the first PHLPP isoform to be characterized, lacks the N-terminal portion of the protein, including the Ras association domain. PHLPP's domain structure influences its ability to dephosphorylate its substrates. A PHLPP construct lacking the PH domain is unable to decrease PKC phosphorylation, while PHLPP lacking the PDZ ligand is unable to decrease Akt phosphorylation.
All radon isotopes are hazardous owing to their radioactivity, gaseous nature, chemical inertness, and radioactivity of their decay products (progeny). Radon-222 is especially dangerous because its longer half-life allows it to permeate soil and rocks, where it is produced in trace quantities from decays of uranium-238, and concentrate in buildings and uranium mines. This contrasts with the other natural isotopes that decay far more quickly (half-lives less than a minute) and thus do not contribute significantly to indoor radiation exposure. At higher concentrations, gaseous 222Rn may be inhaled and decay before exhalation, which leads to accumulation of its short-lived daughters (including alpha-emitters 218Po and 214Po) in the lungs, where they are in intimate contact with the lung cells irradiated; thus, extended periods of exposure to 222Rn and its progeny ultimately induce lung cancer. Alternatively, radon may enter the body through contaminated drinking water or through the decay of ingested radium – making radon diffusion one of the greatest dangers of radium. Thus, 222Rn is a carcinogen; in fact, it is the second leading cause of lung cancer in the United States after cigarette smoking, with over 20,000 deaths per year attributed to radon-induced lung cancer.
Sources: en.wikipedia.org
=== Formulation === The health benefits of a alpha-glucosidase-inhibiting herb powder were shown to be stronger when the powder is consumed orally dissolved in water as a beverage in comparison to its intake as ordinary hard gelatin capsules. The package insert of acarbose tablet lists two ways to take it: chewing it down with the first bites of food, or swallowing it some time before eating. With the same brand of acarbose tablet, chewing food appears effective than swallowing in combating the blood sugar rise from drinking sucrose water.
== Development from 'Peptide 3' == 'Peptide 3' is a 12-amino acid linear peptide corresponding to amino acids 51 to 62 of mature human chemokine CCL2. It is formed from L-amino acids with the sequence NH2-Glu-Ile-Cys-Ala-Asp-Pro-Lys-Gln-Lys-Trp-Val-Gln-OH (or in single letter code NH2-EICADPKQKWVQ-OH). 'Peptide 3' was found to be a Broad-Spectrum Chemokine Inhibitor inhibiting chemotaxis of human myelomonocytic cell line THP-1 monocytes and human neutrophils induced by a range of chemokines including CCL2, CCL3, CXCL8 and CXCL12 with roughly equal potency of 10μM, but not migration induced by other non-chemokine chemoattractants such as n-formyl-Met-Leu-Phe (fMLP) or TGF-β. Biotinylated 'Peptide 3' was found to bind to THP-1 cells with a disassociation constant of roughly 10μM. This suggested that 'Peptide 3' functions as a chemokine receptor antagonist. This mechanism was later proved to not be in action.
The Cape, more specifically the small area around present day Cape Town, was the first part of South Africa to be settled by Europeans. The Dutch East India Company (Vereenigde Oost-Indische Compagnie, VOC) officials did not favour the permanent settlement of Europeans in their trading empire, although during the 140 years of Dutch rule many VOC servants retired or were discharged and remained as private citizens. A small number of longtime VOC employees, however, expressed interest in applying for grants of land with the objective of retiring at the Cape as farmers. In time, they came to form a class of former VOC employees, vrijlieden, also known as vrijburgers (free citizens) who stayed in Dutch territories overseas after serving their contracts. Over generations, this settled European population came to form a distinct identity as Afrikaners (formerly sometimes Afrikaander or Afrikaaner, from the Dutch Africaander) or Boers (farmers). In 1806, the Cape was colonised by the British Empire. Initially British control was aimed to protect the trade route to the East from Napoleon, however, the British soon realised the potential to develop the Cape colony further. Antipathy towards British control and the introduction of new systems and institutions grew amongst a substantial portion of the Afrikaner/Boer community. Between 1834 and 1840 about 15 000 Boers left the Cape Colony in parties of ox-wagons, in search of sovereignty beyond British-claimed territories.
The Hong Kong regional government and the Chinese central government responded to the protests with many administrative measures to quell dissent. In June 2020, the Legislative Council passed the National Anthem Ordinance, which criminalised "insults to the national anthem of China". The Chinese central government meanwhile enacted the Hong Kong national security law to help quell protests in the region. Nine months later, in March 2021, the Chinese central government introduced amendments to Hong Kong's electoral system, which included the reduction of directly elected seats in the Legislative Council and the requirement that all candidates be vetted and approved by a Beijing-appointed Candidate Eligibility Review Committee. In July 2023, Hong Kong's Legislative Council passed reforms slashing directly elected District Council seats and establishing a vetting committee for candidates. In terms of international connectedness, as of 2024, the city was one of eight worldwide that was classified as an "Alpha+" city by the Globalization and World Cities Research Network.
=== 1990s === In the fall of 1990, Kidder appeared as a singer who becomes a murder victim in the Canadian television film White Room (1990). After her car accident, Kidder returned to the screen with an uncredited cameo appearance in the comedy film Delirious (1991), appearing as a woman in a washroom. This was followed by a role as a psychic in To Catch a Killer (1992), a Canadian television thriller film based on the crimes of John Wayne Gacy. She had several small roles in 1994, including in the Disney Channel film Windrunner, as well as another uncredited appearance in Maverick. She played a bartender at the Broken Skull Tavern in Under a Killing Moon, a PC FMV adventure game. Kidder returned to film with a lead role in the independent comedy-drama Never Met Picasso (1997), portraying an actress living with her gay adult son (portrayed by Alexis Arquette), who is attempting to sort his life out. Kevin Thomas of the Los Angeles Times wrote, "Arquette and Kidder [were] given the chance to come across as quite appealing" in their roles. She next appeared in the slasher film The Clown at Midnight (1998), opposite Christopher Plummer, and alongside Lynn Redgrave and James Earl Jones in the romance film The Annihilation of Fish (1999), playing the landlady of an interracial couple. Critic Todd McCarthy in Variety referred to the film as a "would-be charmer" and "a drear moment in the careers of all concerned."
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.